10-Q Filing

GUIDED THERAPEUTICS INC CIK: 924515 Q3 2012

Filing Information

Form Type	10-Q
Accession Number	`0001121781-12-000323`
Period End Date	20120930
Filing Date	20121113
Fiscal Year	2012
Fiscal Period	Q3
XBRL Instance	gthp-20120930.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 68 Income Statement 68 Cash Flow Statement 63

Balance Sheet 68 line items

Line Item	Tag	Value	Unit	Period
Accounts receivable, net of allowance	`AccountsAndNotesReceivableNet`	$7.00K	USD	Point-in-time
Accounts receivable, net of allowance	`AccountsAndNotesReceivableNet`	$20.00K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$3.27M	USD	Point-in-time
Inventory, net of reserves	`InventoryFinishedGoodsNetOfReserves`	$64.00K	USD	Point-in-time
Inventory, net of reserves	`InventoryFinishedGoodsNetOfReserves`	$64.00K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.61M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.20M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.13M	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts of $7 and $20 at September 30, 2012 and December 31, 2011	`AccountsReceivableNet`	$65.00K	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts of $7 and $20 at September 30, 2012 and December 31, 2011	`AccountsReceivableNet`	$117.00K	USD	Point-in-time
Inventory, net of reserves of $64 at September 30, 2012 and December 31, 2011	`InventoryNetOfReservesOf64And0AtDecember312011And2010Respectively`	$520.00K	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Inventory, net of reserves of $64 at September 30, 2012 and December 31, 2011	`InventoryNetOfReservesOf64And0AtDecember312011And2010Respectively`	$461.00K	USD	Point-in-time
Common stock, Authorized	`CommonStockSharesAuthorized`	100,000.00	shares	Point-in-time
Common stock, Authorized	`CommonStockSharesAuthorized`	145,000.00	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$54.00K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$119.00K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$2.89M	USD	Point-in-time
Common stock, Issued	`CommonStockSharesIssued`	52,211.00	shares	Point-in-time
Common stock, Issued	`CommonStockSharesIssued`	62,187.00	shares	Point-in-time
Total current assets	`AssetsCurrent`	$3.25M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$1.27M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$1.03M	USD	Point-in-time
Common stock, outstanding	`CommonStockSharesOutstanding`	62,187.00	shares	Point-in-time
Common stock, outstanding	`CommonStockSharesOutstanding`	52,211.00	shares	Point-in-time
Other assets	`AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment`	$386.00K	USD	Point-in-time
Other assets	`AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment`	$247.00K	USD	Point-in-time
Total noncurrent assets	`AssetsNoncurrent`	$1.52M	USD	Point-in-time
Total noncurrent assets	`AssetsNoncurrent`	$1.42M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$4.77M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$4.31M	USD	Point-in-time
Short-term notes payable	`ShorttermNotesPayable`	$30.00K	USD	Point-in-time
Short-term notes payable	`ShorttermNotesPayable`	-	USD	Point-in-time
Current portion of long-term debt	`ShortTermBorrowings`	$25.00K	USD	Point-in-time
Current portion of long-term debt	`ShortTermBorrowings`	$11.00K	USD	Point-in-time
Notes payable - past due	`NotesPayablePastDue`	$406.00K	USD	Point-in-time
Notes payable - past due	`NotesPayablePastDue`	$362.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$1.10M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$1.04M	USD	Point-in-time
Accrued liabilities	`AccruedLiabilitiesCurrent`	$757.00K	USD	Point-in-time
Accrued liabilities	`AccruedLiabilitiesCurrent`	$608.00K	USD	Point-in-time
Deferred revenue	`DeferredRevenue`	$582.00K	USD	Point-in-time
Deferred revenue	`DeferredRevenue`	$453.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$2.65M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$2.73M	USD	Point-in-time
Long-term debt payable, less current portion	`LongtermDebtPayableLessCurrentPortion`	-	USD	Point-in-time
Long-term debt payable, less current portion	`LongtermDebtPayableLessCurrentPortion`	$4.00K	USD	Point-in-time
Total long-term liabilities	`LongTermDebt`	-	USD	Point-in-time
Total long-term liabilities	`LongTermDebt`	$4.00K	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$2.65M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$2.73M	USD	Point-in-time
Common stock, $.001 par value; 145,000 and 100,000 shares authorized, 62,187 and 52,211 shares issued and outstanding, as of September 30, 2012 and December 31, 2011, respectively	`CommonStockValue`	$62.00K	USD	Point-in-time
Common stock, $.001 par value; 145,000 and 100,000 shares authorized, 62,187 and 52,211 shares issued and outstanding, as of September 30, 2012 and December 31, 2011, respectively	`CommonStockValue`	$52.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$86.61M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$92.97M	USD	Point-in-time
Treasury stock, at cost	`TreasuryStockValue`	$104.00K	USD	Point-in-time
Treasury stock, at cost	`TreasuryStockValue`	$104.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-85.09M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-90.91M	USD	Point-in-time
TOTAL GUIDED THERAPEUTICS STOCKHOLDERS' EQUITY	`TotalGuidedTherapeuticsStockholdersEquity`	$1.47M	USD	Point-in-time
TOTAL GUIDED THERAPEUTICS STOCKHOLDERS' EQUITY	`TotalGuidedTherapeuticsStockholdersEquity`	$2.02M	USD	Point-in-time
Non-controlling interest	`MinorityInterest`	$104.00K	USD	Point-in-time
Non-controlling interest	`MinorityInterest`	$104.00K	USD	Point-in-time
TOTAL STOCKHOLDERS' EQUITY	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.58M	USD	Point-in-time
TOTAL STOCKHOLDERS' EQUITY	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$2.12M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$4.31M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$4.77M	USD	Point-in-time

Income Statement 68 line items

Line Item	Tag	Value	Unit	Period
Contract and grant revenue	`Revenues`	$693.00K	USD	1 Quarter
Contract and grant revenue	`Revenues`	$2.33M	USD	3 Qtrs
Contract and grant revenue	`Revenues`	$2.70M	USD	3 Qtrs
Contract and grant revenue	`Revenues`	$1.02M	USD	1 Quarter
Sales - devices and disposables	`SalesDevicesAndDisposables`	-	USD	1 Quarter
Sales - devices and disposables	`SalesDevicesAndDisposables`	$72.00K	USD	3 Qtrs
Sales - devices and disposables	`SalesDevicesAndDisposables`	$43.00K	USD	1 Quarter
Sales - devices and disposables	`SalesDevicesAndDisposables`	-	USD	3 Qtrs
Cost of goods sold	`CostOfGoodsSold`	$55.00K	USD	1 Quarter
Cost of goods sold	`CostOfGoodsSold`	$130.00K	USD	3 Qtrs
Cost of goods sold	`CostOfGoodsSold`	-	USD	1 Quarter
Cost of goods sold	`CostOfGoodsSold`	-	USD	3 Qtrs
Gross Loss	`GrossProfit`	$-58.00K	USD	3 Qtrs
Gross Loss	`GrossProfit`	$-12.00K	USD	1 Quarter
Gross Loss	`GrossProfit`	-	USD	3 Qtrs
Gross Loss	`GrossProfit`	-	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$2.40M	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$709.00K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$787.00K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$2.02M	USD	3 Qtrs
Sales and marketing	`SellingAndMarketingExpense`	$271.00K	USD	3 Qtrs
Sales and marketing	`SellingAndMarketingExpense`	$132.00K	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$80.00K	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$200.00K	USD	3 Qtrs
Claim settlement	`ClaimSettlement`	$2.29M	USD	3 Qtrs
Claim settlement	`ClaimSettlement`	-	USD	3 Qtrs
Claim settlement	`ClaimSettlement`	$2.29M	USD	1 Quarter
Claim settlement	`ClaimSettlement`	-	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$2.07M	USD	3 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$596.00K	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$732.00K	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$2.71M	USD	3 Qtrs
Total	`OperatingExpenses`	$6.58M	USD	3 Qtrs
Total	`OperatingExpenses`	$1.65M	USD	1 Quarter
Total	`OperatingExpenses`	$3.67M	USD	1 Quarter
Total	`OperatingExpenses`	$5.38M	USD	3 Qtrs
Operating loss	`OperatingIncomeLoss`	$-2.65M	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-970.00K	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-3.11M	USD	3 Qtrs
Operating loss	`OperatingIncomeLoss`	$-3.87M	USD	3 Qtrs
OTHER INCOME	`OtherIncome`	$53.00K	USD	3 Qtrs
OTHER INCOME	`OtherIncome`	-	USD	3 Qtrs
OTHER INCOME	`OtherIncome`	-	USD	1 Quarter
OTHER INCOME	`OtherIncome`	$9.00K	USD	1 Quarter
INTEREST EXPENSE	`InterestExpense`	$21.00K	USD	1 Quarter
INTEREST EXPENSE	`InterestExpense`	$62.00K	USD	3 Qtrs
INTEREST EXPENSE	`InterestExpense`	$16.00K	USD	1 Quarter
INTEREST EXPENSE	`InterestExpense`	$52.00K	USD	3 Qtrs
LOSS BEFORE INCOME TAXES	`LossBeforeIncomeTaxes`	$986.00K	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`LossBeforeIncomeTaxes`	$3.17M	USD	3 Qtrs
LOSS BEFORE INCOME TAXES	`LossBeforeIncomeTaxes`	$3.88M	USD	3 Qtrs
LOSS BEFORE INCOME TAXES	`LossBeforeIncomeTaxes`	$2.66M	USD	1 Quarter
PROVISION FOR INCOME TAXES	`IncomeTaxReconciliationOtherReconcilingItems`	-	USD	1 Quarter
PROVISION FOR INCOME TAXES	`IncomeTaxReconciliationOtherReconcilingItems`	-	USD	1 Quarter
PROVISION FOR INCOME TAXES	`IncomeTaxReconciliationOtherReconcilingItems`	-	USD	3 Qtrs
PROVISION FOR INCOME TAXES	`IncomeTaxReconciliationOtherReconcilingItems`	-	USD	3 Qtrs
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLERS	`NetIncomeLoss`	$-3.17M	USD	3 Qtrs
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLERS	`NetIncomeLoss`	$-3.88M	USD	3 Qtrs
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLERS	`NetIncomeLoss`	$-2.66M	USD	1 Quarter
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLERS	`NetIncomeLoss`	$-986.00K	USD	1 Quarter
BASIC AND DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS	`EarningsPerShareBasicAndDiluted`	$-0.02	USD	1 Quarter
BASIC AND DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS	`EarningsPerShareBasicAndDiluted`	$-0.08	USD	3 Qtrs
BASIC AND DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS	`EarningsPerShareBasicAndDiluted`	$-0.06	USD	3 Qtrs
BASIC AND DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS	`EarningsPerShareBasicAndDiluted`	$-0.05	USD	1 Quarter
WEIGHTED AVERAGE SHARES OUTSTANDING	`WeightedAverageNumberOfSharesOutstandingBasic`	60,827.00	shares	1 Quarter
WEIGHTED AVERAGE SHARES OUTSTANDING	`WeightedAverageNumberOfSharesOutstandingBasic`	48,813.00	shares	1 Quarter
WEIGHTED AVERAGE SHARES OUTSTANDING	`WeightedAverageNumberOfSharesOutstandingBasic`	55,810.00	shares	3 Qtrs
WEIGHTED AVERAGE SHARES OUTSTANDING	`WeightedAverageNumberOfSharesOutstandingBasic`	48,379.00	shares	3 Qtrs

Cash Flow Statement 63 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-3.17M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-3.88M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-2.66M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-986.00K	USD	1 Quarter
Bad debt expense (recovery)	`BadDebtRecovery`	-	USD	3 Qtrs
Bad debt expense (recovery)	`BadDebtRecovery`	$-8.00K	USD	3 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$258.00K	USD	3 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$18.00K	USD	3 Qtrs
Stock based compensation	`ShareBasedCompensation`	$347.00K	USD	3 Qtrs
Stock based compensation	`ShareBasedCompensation`	$493.00K	USD	3 Qtrs
Issuance of warrants in connection with settlement of claim	`IssuanceOfWarrantsInConnectionWithSettlementOfClaim`	$2.29M	USD	3 Qtrs
Issuance of warrants in connection with settlement of claim	`IssuanceOfWarrantsInConnectionWithSettlementOfClaim`	-	USD	3 Qtrs
Inventory	`IncreaseDecreaseInInventories`	-	USD	3 Qtrs
Inventory	`IncreaseDecreaseInInventories`	$60.00K	USD	3 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-39.00K	USD	3 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$59.00K	USD	3 Qtrs
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-10.00K	USD	3 Qtrs
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-64.00K	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-62.00K	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$220.00K	USD	3 Qtrs
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$39.00K	USD	3 Qtrs
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$129.00K	USD	3 Qtrs
Accrued liabilities	`IncreaseDecreaseInAccruedLiabilities`	$-156.00K	USD	3 Qtrs
Accrued liabilities	`IncreaseDecreaseInAccruedLiabilities`	$44.00K	USD	3 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$-585.00K	USD	3 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$139.00K	USD	3 Qtrs
Total adjustments	`AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$2.12M	USD	3 Qtrs
Total adjustments	`AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$1.05M	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInContinuingOperations`	$-2.12M	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInContinuingOperations`	$-1.76M	USD	3 Qtrs
Additions to capitalized software costs	`CapitalizedComputerSoftwareAdditions`	-	USD	3 Qtrs
Additions to capitalized software costs	`CapitalizedComputerSoftwareAdditions`	$-184.00K	USD	3 Qtrs
Additions to fixed assets	`AdditionsToNoncurrentAssets`	$-264.00K	USD	3 Qtrs
Additions to fixed assets	`AdditionsToNoncurrentAssets`	$-496.00K	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-496.00K	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-448.00K	USD	3 Qtrs
Proceeds from options and warrants exercised	`ProceedsFromWarrantExercises`	$3.07M	USD	3 Qtrs
Proceeds from options and warrants exercised	`ProceedsFromWarrantExercises`	$14.20	USD	Point-in-time
Proceeds from options and warrants exercised	`ProceedsFromWarrantExercises`	$245.00K	USD	3 Qtrs
Payments on notes and loan payables	`PaymentsOfLoanCosts`	$50.00K	USD	3 Qtrs
Payments on notes and loan payables	`PaymentsOfLoanCosts`	$173.00K	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$72.00K	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$3.02M	USD	3 Qtrs
NET CHANGE IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$409.00K	USD	3 Qtrs
NET CHANGE IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-2.14M	USD	3 Qtrs
CASH AND CASH EQUIVALENTS, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$3.27M	USD	Point-in-time
CASH AND CASH EQUIVALENTS, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$2.61M	USD	Point-in-time
CASH AND CASH EQUIVALENTS, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$2.20M	USD	Point-in-time
CASH AND CASH EQUIVALENTS, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$1.13M	USD	Point-in-time
CASH AND CASH EQUIVALENTS, end of period	`CashAndCashEquivalentsAtCarryingValue`	$3.27M	USD	Point-in-time
CASH AND CASH EQUIVALENTS, end of period	`CashAndCashEquivalentsAtCarryingValue`	$2.61M	USD	Point-in-time
CASH AND CASH EQUIVALENTS, end of period	`CashAndCashEquivalentsAtCarryingValue`	$2.20M	USD	Point-in-time
CASH AND CASH EQUIVALENTS, end of period	`CashAndCashEquivalentsAtCarryingValue`	$1.13M	USD	Point-in-time
Cash paid for Interest	`InterestPaid`	$12.00K	USD	3 Qtrs
Cash paid for Interest	`InterestPaid`	$2.00K	USD	3 Qtrs
Conversion of accounts payable into common stock	`ConversionOfAccountsPayableIntoCommonStock`	$27.00K	USD	3 Qtrs
Conversion of accounts payable into common stock	`ConversionOfAccountsPayableIntoCommonStock`	-	USD	3 Qtrs
Deemed dividends in the form of convertible warrants into common stock	`DeemedDividendsInFormOfConvertibleWarrantsIntoCommonStock`	-	USD	3 Qtrs
Deemed dividends in the form of convertible warrants into common stock	`DeemedDividendsInFormOfConvertibleWarrantsIntoCommonStock`	$2.65M	USD	3 Qtrs
Conversion of interest to principal	`ConversionOfInterestToPrincipal`	$25.00K	USD	3 Qtrs
Conversion of interest to principal	`ConversionOfInterestToPrincipal`	-	USD	3 Qtrs
Conversion of deferred compensation into common stock	`ConversionOfDeferredCompensationIntoCommonStock`	$148.00K	USD	3 Qtrs
Conversion of deferred compensation into common stock	`ConversionOfDeferredCompensationIntoCommonStock`	-	USD	3 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.